US 12,123,874 B2
Reagent compounds, compositions, kits, and methods for amplified assays
David A. Schwartz, Encinitas, CA (US); and Stephen J. Kron, Oak Park, IL (US)
Assigned to CELL IDX, INC., San Diego, CA (US); and THE UNIVERSITY OF CHICAGO, Chicago, IL (US)
Appl. No. 16/318,793
Filed by CELL IDX, INC., San Diego, CA (US); and THE UNIVERSITY OF CHICAGO, Chicago, IL (US)
PCT Filed Jul. 18, 2017, PCT No. PCT/US2017/042656
§ 371(c)(1), (2) Date Jan. 18, 2019,
PCT Pub. No. WO2018/017604, PCT Pub. Date Jan. 25, 2018.
Claims priority of provisional application 62/363,821, filed on Jul. 18, 2016.
Prior Publication US 2019/0265235 A1, Aug. 29, 2019
Int. Cl. G01N 33/547 (2006.01); C12N 9/04 (2006.01); C12N 9/08 (2006.01); C12N 9/16 (2006.01); C12Q 1/6804 (2018.01); C12Q 1/682 (2018.01); G01N 33/533 (2006.01); G01N 33/535 (2006.01); G01N 33/543 (2006.01)
CPC G01N 33/547 (2013.01) [C12N 9/0006 (2013.01); C12N 9/0065 (2013.01); C12N 9/16 (2013.01); C12Q 1/6804 (2013.01); C12Q 1/682 (2013.01); G01N 33/533 (2013.01); G01N 33/535 (2013.01); G01N 33/54353 (2013.01); C12Y 101/03004 (2013.01); C12Y 111/01007 (2013.01); C12Y 301/03001 (2013.01)] 17 Claims
OG exemplary drawing
 
1. A diagnostic kit comprising:
a first reagent compound comprising a bridging peptide coupled to a tyramide moiety, said bridging peptide being selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5;
a first detectable antibody having specificity for the bridging peptide with high affinity, wherein the first detectable antibody comprises a detectable label, said first detectable antibody being a monoclonal antibody; and
instructions for use.